GenScript Biotech
From Wikipedia, the free encyclopedia
 | |
| Company type | Public |
|---|---|
| SEHK: 1548 | |
| Industry | Life sciences |
| Founded | 2002 in New Jersey[1] |
| Founders | Fangliang Zhang, Ye Wang, Luquan Wang |
| Headquarters | Nanjing[2], |
Area served | Worldwide |
Key people | Shao Weihui, CEO |
| Website | www |
GenScript Biotech, fully known as GenScript Biotech Corporation, usually referred to as simply GenScript, is a China–based biotech company.[3][4][5][6] It was co-founded in 2002 in New Jersey by Fangliang Zhang, Ye Wang, and Luquan Wang.[7] The company mainly provides life science research application instruments and services.[8] It was listed on the Hong Kong Stock Exchange in 2015.[9] The current rotating CEO of the firm is Shao Weihui, who also served as the chief operating officer and Chinese Communist Party Committee Secretary for the company.[10][11] The company's main subsidiaries include Legend Biotech,[12] ProBio Technology,[13] and Bestzyme.[14]
Outside of the United States, GenScript has established presences in China, Singapore, Japan, the United Kingdom, and the Netherlands, among others.[15] The company's operations are divided into four main segments, CDMO platform, life-science services and products platform, integrated cell therapy platform, and industrial synthetic products platform.[15] In September 2021, the firm and its subsidiary Probio received series A funding from Hillhouse Capital.[16]